Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling
Open Access
- 14 April 2026
- journal article
- perspective
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (4) , e70251
Abstract
Pharmacometric covariate analyses support both mechanistic understanding and clinical decision‐making, that is, two different objectives which require different analysis targets. Adopting the ICH E9(R1) estimand framework clarifies this distinction, reconciling mechanistic modeling (conditional covariate effects) with regulatory and clinical needs (unconditional covariate effects), clarifying that estimand definition, i.e. the objective, and not the estimator, is the first choice to make in covariate modeling. This structured approach optimizes quantitative evidence for communicating clinical impact and patient care.Keywords
This publication has 8 references indexed in Scilit:
- Conditional Versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and ReportingCPT: Pharmacometrics & Systems Pharmacology, 2026
- The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects modelsJournal of Pharmacokinetics and Pharmacodynamics, 2025
- An introduction to causal inference for pharmacometriciansCPT: Pharmacometrics & Systems Pharmacology, 2022
- An introduction to the full random effects modelCPT: Pharmacometrics & Systems Pharmacology, 2022
- Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and DocumentationCPT: Pharmacometrics & Systems Pharmacology, 2015
- The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier CoefficientsAmerican Journal of Epidemiology, 2013
- Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author)Statistical Science, 2001
- Clinical pharmacology and the choice between theory and empiricismClinical Pharmacology & Therapeutics, 1989